Items 1 ~ 10 of 2104, Page 1 of 210    Go to Headlines
  06/21/2019 Medtronic
Medtronic Supports CMS Ruling on TAVR National Coverage Determination
- Medtronic plc (NYSE:MDT) today issued the following statement regarding the final decision memo updating the TAVR National Coverage Determination (NCD) 20.32 announced by the Centers for Medicare & Medicaid Services (CMS)
  06/21/2019 Medtronic
Medtronic Announces 8 Percent Increase in Cash Dividend
- 42nd Consecutive Year of Dividend Increases
  06/20/2019 MERCK
Merck Hosts 2019 Investor Day Outlining Business Momentum, Strong Expected Growth and Focus on Innovative Research and Development
  06/20/2019 Medtronic
Medtronic Statement Regarding FDA Circulatory System Devices Panel
- Medical Devices Advisory Committee on paclitaxel-coated therapies in patients with peripheral artery disease (PAD) in the superficial femoropopliteal artery (SFA)
  06/19/2019 MERCK
AstraZeneca and Merck’s LYNPARZA® (olaparib) Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer
- LYNPARZA is the Only PARP Inhibitor Approved in Japan
  06/19/2019 Abbott
Abbott Hosts Conference Call for Second-Quarter Earnings
- ABBOTT PARK, Ill., June 19, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2019 financial results on Wednesday, July 17, 2019, before the market opens.
  06/18/2019 MERCK
LYNPARZA® (olaparib) Approved in the EU for Use as First-Line Maintenance Therapy in Patients With BRCA-Mutated Advanced Ovarian Cancer
- AstraZeneca and Merck’s LYNPARZA Reduced the Risk of Disease Progression or Death by 70% Compared to Placebo Following Response to Platinum-Based Chemotherapy in Phase 3 SOLO-1 Trial / LYNPARZA is the Only PARP Inhibitor Approved in the EU for This Indication
  06/18/2019 MERCK
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy
- Marks First Approval for KEYTRUDA in SCLC
  06/17/2019 Abbott
Abbott Launches First-ever Rapid Point-of-Care HbA1c Test to Aid in the Diagnosis of Diabetes
- Afinion™ HbA1c Dx test provides results in three minutes, enabling clinicians to develop informed, individualized care plans during patient consultation / Assay is the first and only rapid point-of-care test cleared by the U.S. Food and Drug Administration (FDA) to aid healthcare professionals in the diagnosis of diabetes
  06/14/2019 Abbott
Abbott Declares 382ⁿ? Consecutive Quarterly Dividend
- ABBOTT PARK, Ill., June 14, 2019 /PRNewswire/ --?The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 32 cents per share.

<<  <  [1[2]  [3]  [4]  [5]  [6]  [7]  [8]  [9]  [10]  >  >>